Meeting
2023 ASCO Annual Meeting
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
Authors
Hongyun Zhao
Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Hongyun Zhao , Yuxiang Ma , Nong Yang , Zhehai Wang , Wenjian Jin , Xingya Li , Yunpeng Liu , Rui Meng , Jianying Zhou , Ying Cheng , Yongsheng Wang , Zhuang Yu , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05441956
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9113)
DOI
10.1200/JCO.2023.41.16_suppl.9113
Abstract #
9113
Poster Bd #
101
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.
First Author: Simon Baldacci
Poster
2018 ASCO Annual Meeting
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
First Author: Benjamin Besse
Poster
2020 ASCO Virtual Scientific Program
Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2015 ASCO Annual Meeting
Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.
First Author: Todd Michael Bauer